Many tumors possess mechanisms to avoid destruction by the immune system. For instance, they misuse the natural “brakes” in the immune defense mechanism, which normally prevent an excessive immune response. Researchers at the University of Bonn have now been able to take off one of these brakes. The study, which involved colleagues from Hamburg and Würzburg, could pave the way for more effective cancer therapies. It is being published in the journal Cell Reports.
Killer T cells are a powerful weapon of the immune system. Following a viral infection, for instance, they swarm out in huge numbers and destroy all of the infected body cells. Their destructive power is also directed towards cancer cells – at least in principle. Many tumors have actually developed mechanisms that allow them to outmaneuver this defensive weapon.
To do this, abuse the so-called regulatory T cells, for example. These are also part of the immune system, but fulfill an opposite function there: they suppress the immune response and thus prevent killer T cells from attacking healthy tissue in the body.
Tumors exploit this by pretending to belong to the body’s own tissue. They can thus be protected to a certain degree by the regulatory T cells. “We have now found a way to kill off the regulatory T cells,” explains Christoph Heuser, a doctoral candidate at the Institute of Experimental Immunology at the University of Bonn. “We were thus able to significantly increase the impact of the killer T cells.”
The study focuses on a protein produced naturally in the body called IKKβ, which has been known for long to promote the activation of immune cells. It is thus considered an immunostimulant. “We have now blocked IKKβ in a test tube with the help of a pharmaceutical ingredient,” says Heuser’s colleague Dr. Janine Gotot. “The regulatory T cells died off afterward. However, the killer T cells survived and even gained in impact because they were no longer inhibited by the regulatory T cells.”
The researchers then tested using mice with skin cancer whether the IKKß inhibitor could be suitable for tumor treatment. This cancer is nowadays treated by vaccination and by immunotherapies, but these measures are often not effective enough. However, the researchers treated the rodents with the IKKß inhibitor shortly after the vaccination. Following around two weeks of treatment, the number of regulatory T cells fell by half. The response of the killer T cells to the tumor was correspondingly stronger. The cancer growth was delayed significantly by this, and the animals survived for longer.
Combination therapy against tumors
“Nevertheless, complete healing cannot be achieved solely by inhibiting IKKß,” relativized Prof. Christian Kurts, Director of the Institute of Experimental Immunology at the University of Bonn. “By combining with other immunological active pharmaceutical ingredients, it may, however, be possible to stimulate the immune system to more effectively combat the cancer.”
The regulatory T cells are actually only one element among many others with which the body keeps its immune cells in check. Experts also refer to these braking mechanisms as “immunological checkpoints”. In recent years, the researchers have succeeded in releasing these brakes using suitable inhibiting substances (the “checkpoint inhibitors”). “This approach has already revolutionized the treatment of cancer,” says Kurts. The University of Bonn is heavily involved in the development and clinical testing of such therapies, including as part of the center for integrated oncology (CIO), the cluster of excellence ImmunoSensation and the German-Australian research training group Bo&MeRanG.
Publication: Christoph Heuser, Janine Gotot, Eveline C. Piotrowski, Marie-Sophie Philipp, Christina Johanna Felicia Courrèges, Martin Sylvester Otte, Linlin Guo, Jonathan Leo Schmid-Burgk, Veit Hornung, Annkristin Heine, Percy Alexander Knolle, Natalio Garbi, Edgar Serfling, César Evaristo, Friedrich Thaiss, Christian Kurts: Prolonged IKKβ inhibition improves ongoing CTL antitumor responses by incapacitating regulatory T cells
Prof. Christian Kurts
Director of the Institute of Experimental Immunology
University of Bonn
Tel. +49 (0)228/28711051
Johannes Seiler | idw - Informationsdienst Wissenschaft
Scientists develop tiny tooth-mounted sensors that can track what you eat
22.03.2018 | Tufts University
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.
The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...
In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.
Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...
Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.
They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...
A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
22.03.2018 | Trade Fair News
22.03.2018 | Earth Sciences
22.03.2018 | Earth Sciences